Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Basmisanil - Roche

Next Previous
Search
Drug Profile

Basmisanil - Roche

Alternative Names: GABRA5 negative allosteric modulator (NAM) - Roche; NTX-1511; RG-1662; RO-5186582

Latest Information Update: 26 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Roche
  • Class Antidementias; Oxazoles; Pyridines; Small molecules; Thiamorpholines
  • Mechanism of Action GABA A alpha 5 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chromosome disorders; Down syndrome; Neurological disorders; Schizophrenia

Most Recent Events

  • 13 Feb 2025 RO 7308480 licensed to Newleos Therapeutics
  • 04 Mar 2024 Discontinued - Phase-II for Chromosome disorders (In adolescents, In children) in USA, Portugal, Poland (PO) (NCT05307679)
  • 04 Mar 2024 Roche terminates a phase II trial in Chromosome disorders (In adolescents, In children) in USA, Australia, Poland, Portugal, Spain and the UK (PO), due to slow recruitment, sponsor decision and not related to safety or tolerability.(NCT05307679)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top